Deyaa Adib, MD, on Optimizing Manufacturing of Solid Tumor Cell Therapies


The chief medical officer of Triumvira Immunologics discussed the company’s future plans.

“We are planning to be able to treat over 2000 patients next year. So by commissioning additional Cocoons from Lonza, with this state-of-the-art technology, our yield has been 100%.”

The HER2-targeted T-cell antigen coupler (TAC) T-cell therapy TAC01-HER2 (Triumvira Immunologics) demonstrated early signs of clinical activity and a manageable safety profile, according to updated data from the phase 1/2 TACTIC-2 study (NCT04727151). A patient with stage 4b gastric cancer treated with TAC01-HER2 had a partial response and those in cohort 2 experienced a disease control rate of 75%.

The trial will be enrolling in its phase 2 portion in the beginning of 2023. These data were presented at the European Society for Medical Oncology (ESMO) Congress 2022, taking place September 9-13, in Paris, France, and virtually, by Benjamin L. Schlechter, MD, instructor, medicine, Harvard Medical School, and Dana-Farber Cancer Institute.

CGTLive spoke with the senior author of the poster, Deyaa Adib, MD, who is chief medical officer of Triumvira Immunologics, to learn more about Triumvira’s programs and technologies. He discussed an upcoming investigational new drug application (IND) submission in 2023 for claudin 18.2-positive cancers including gastric, pancreatic, ovarian, and lung cancers. He also discussed Lonza’s Cocoon technology that Triumvira is using in its programs and its advantages in the space.

Click here to read more coverage of ESMO Congress 2022.

Schlechter BL, Ileana Dumbrava EE, Olson D, et al. A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors. Presented at: ESMO Congress 2022, September 9-13, Paris, France. Poster #778TiP
Related Videos
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
© 2024 MJH Life Sciences

All rights reserved.